BEST UNLIMITED TURBO SHORT CERTIFICATE - ASTRAZENECA | Market Closed - Borsa Italiana 16:04:59 2024-07-02 EDT | ||
| 1.142 EUR | +27.31% |
|
| Current month | +43.78% | ||
| 1 month | +21.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-07-02 | 1.142 | +27.31% |
| 24-07-01 | 0.897 | +7.30% |
| 24-06-28 | 0.836 | +2.20% |
| 24-06-27 | 0.818 | +32.15% |
| 24-06-26 | 0.619 | -5.93% |
Real-time Borsa Italiana
Last update July 02, 2024 at 04:04 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| S35526 | |
| ISIN | DE000SW9K4H6 |
| Date issued | 2024-04-30 |
| Strike | 13,028 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.386 € |
|---|---|
| Lowest since issue | 0.465 € |
| Spread | 0.08 € |
| Spread % | 6.80% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
155.5
USD
Average target price
174.6
USD
Spread / Average Target
+12.26%
- Stock Market
- Certificates
- S35526 Certificat
